Compare Medpace Holdings Inc (MEDP) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs SYSCO Corporation — how do they compare? Medpace Holdings Inc trades at $598 (market cap $16.90B), while SYSCO Corporation trades at $85.47 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 2.4× Medpace Holdings Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SYY | |
|---|---|---|
Market Cap | $16.90B | $40.32B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $91.16 |
52-Week Low | $393.42 | $69.30 |
Enterprise Value | $16.52B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Sysco (SYY) trades at $84.73, up 1.03% today, with a bullish technical signal from moving averages and a consensus analyst price target of $88.25. The company reported strong Q4 2026 earnings, beating EPS estimates with $1.53 versus $1.51 expected, driven by U.S. foodservice volume growth and cost efficiencies. Revenue reached $81.37 billion in 2025, with net income of $1.83 billion, though profit margins remain thin at 2.08%. Recent news highlights CEO discussions on CNBC and operational initiatives, including AI-driven efficiencies.
The outlook for SYY is positive, supported by earnings beats, steady cash flow, and analyst optimism, but risks include competitive pressures, supply chain disruptions, and macroeconomic uncertainty. Upside potential exists if the company maintains volume growth and margin improvements, but investors should monitor debt levels and food safety issues highlighted in recent reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
